Fundai

Jaber Ebne Hayyan Pharmaceutical Company (DJABER) cash flow statement

Operating, investing and financing cash flows, and the closing balance

Ticker
DJABER
Industry
Pharmaceuticals
Market
Tehran Stock Exchange

Latest periods

Latest 9-month periods, in million rials
ItemTo 1405/06/31To 1404/06/31To 1403/06/31To 1402/09/30To 1401/09/30To 1400/09/30
Cash generated from operations-1,790,252-870,581-536,33376,035-546,288-32,817
Cash payments for income tax-297,997-320,064-23,713-27,137-78,889-92
Net cash inflow (outflow) from operating activities-2,088,249-1,190,645-560,04648,898-625,177-32,909
Cash receipts from dividends334,940121,850581,79748412,848344,118
Net cash inflow (outflow) from investing activities334,940109,8632,765,558328,6751,440,756203,985
Net cash inflow (outflow) before financing activities-1,753,309-1,080,7822,205,512377,573815,579171,076
Cash receipts from facilities5,908,7173,340,7443,243,5685,759,4195,270,1040
Cash payments for principal of loans-3,436,632-2,922,498-3,947,529-4,765,215-5,040,201-5,739,738
Cash payments for interest on loans-541,241-621,816-692,829-721,875-517,686-387,857
Cash payments for dividends-343,939-2,756,837-824,403-987,901-435,832-135,879
Net cash inflow (outflow) from financing activities1,586,905-2,960,407-2,221,193-715,572-723,615-90,974
Net increase (decrease) in cash-166,404-4,041,189-15,681-337,99991,96480,102
Cash balance at beginning of year505,6095,134,127327,404664,70852,17699,419
Effect of changes in exchange rates-52,918-13,3080695817-117
Cash balance at end of year286,2871,079,630311,723327,404144,957179,404
Non-cash transactions57,6160663,9371,209,77200

Reporting periods

79 periods are on file for this report, from the period ending 1380/12/29 to the period ending 1405/06/31.